Prescription Medicines
HYALBONE Plus Once Inj.
- Product Category
- Osteoarthritis treatment
- Active Ingredients
- 4:1 w/w mixed gel of sodium hyaluronate gel and sodium hyaluronate solution cross-linked with divinylsulfone
- Appearance
- An injection containing a colorless, transparent, viscoelastic gel in a glass tube (prefilled syringe) closed with a rubber stopper at the top and bottom.
- Reimbursement Code
- 648104581
01 / 02
1. Composition and Strength : 1 prefilled syringe (2mL)
- Active ingredient: 4:1 w/w mixed gel of sodium hyaluronate gel and sodium hyaluronate solution cross-linked with divinyl sulfone (in-house specification) --- 2.04g (40mg as sodium hyaluronate)
- Additives: Sterile needle
2. Effectiveness
osteoarthritis of the knee joint
3. Dosage and dosage
Adults: Administer 1 tube at a time into the knee joint cavity, but administer appropriately considering the interval of administration (6 months or more) depending on symptoms.
4. Precautions for use
1. Do not administer to the following patients:
1) Patients with a history of hypersensitivity to this drug or its components
2) Patients with infection or severe inflammation in the joint space of administration
3) Patients with infection or skin disease on the skin at the injection site
2. Administer with caution to the following patients:
1) Patients with a history of hypersensitivity to other drugs
2) Patients with hepatic impairment or its history
3. Adverse reactions
1) No serious adverse reactions related to this drug occurred.
2) In a clinical trial (YY_YYD302_003) of this drug in patients with knee osteoarthritis using Shinobianju as the control group, the frequency of adverse reactions at the injection site following intra-articular administration was 48.42% (46/95 patients) after the first administration of this drug and 47.27% (26/55 patients) after re-administration. Reported injection site adverse reactions are listed in Table 1 below. Severe adverse reactions were reported in the following order: swelling (9.47% for this drug, 7.27% after re-administration of this drug), erythema (6.32%, 3.64% after re-administration of this drug), and pain (3.16% for this drug, 12.73% after re-administration of this drug). Adverse reactions at the injection site that persisted for more than 7 days after administration of this drug were pain 5.26%, heat 3.16%, and swelling 1.05%, all of which disappeared within 14 days without special treatment. After re-administration, pain 10.91%, swelling 5.45%, heat 3.64%, and erythema 1.82% all disappeared without special treatment.
Table 1. Adverse reactions at the injection site reported in the first administration and re-administration clinical trial of this drug (YY_YYD302_003)
*Table 1. : Refer to manual
3) In a clinical trial of this drug (YY_YYD302_003) using Shinobianju as the control group for patients with knee osteoarthritis, the frequency of adverse reactions excluding injection site reactions was 9.47% (9/95 patients, 19 cases) during the 12 weeks after the first administration of this drug and 29.09% (16/55 patients, 35 cases) during the 36 weeks after the first administration of this drug. The rate was 14.55% (8/55 people, 13 cases) for 12 weeks after re-administration of the drug. Most cases were mild to moderate. Adverse reactions reported with a frequency of more than 1% after administration of this drug are listed in Table 2 below.
Table 2. Adverse reactions reported by more than 1% in the first administration and re-administration clinical trials of this drug (YY_YYD302_003)
*Table 2. : Refer to manual
4. General precautions
1) If there is severe inflammation in the joint due to osteoarthritis of the knee, administration of this drug may cause worsening of local inflammatory symptoms, so it is advisable to administer this drug after eliminating the inflammatory symptoms.
2) Since local pain, erythema, and swelling are very common with the administration of this drug, avoid vigorous exercise or actions that put strain on the joints for 48 hours after administering this drug to the joint space, and take measures such as instructing local rest.
3) This drug may cause pain if it leaks outside the joint space, so be sure to administer it within the joint space.
4) This drug must be administered by an experienced doctor.
5. Interaction
The safety and effectiveness of interactions between this drug and other intra-articular agents have not been proven, so do not administer it together.
6. Administration to pregnant and lactating women
The safety and effectiveness of this drug in pregnant and lactating women have not been established, so administration of this drug is not recommended.
7. Administration to children
Because the safety and effectiveness of this drug in children have not been established, its administration is not recommended.
8. Administration to elderly people
In general, elderly people have reduced physiological function, so caution should be exercised when administering this drug. In two clinical trials, 55.4% (118/213 people) of the total test subjects were elderly people aged 65 years or older who were administered this drug, and there was no difference in response to the drug between elderly and non-elderly people.
9. Application precautions
1) Since this drug is administered into the knee joint space, it must be administered under strict sterile conditions.
2) If there is retention of joint fluid, remove the exudate by paracentesis as necessary and then administer the drug.
3) Do not administer intravascularly, extra-articularly, or into synovial tissue.
4) It is recommended to administer this medicine using the enclosed needle.
5) Be careful because this drug may cause precipitation due to quaternary ammonium salts such as benzalkonium chloride, a disinfectant, and chlorhexidine.
6) This medicine is for one-time use and cannot be re-sterilized or reused. Do not use if package or syringe is open or appears damaged.
7) The injection site must be disinfected with alcohol or other appropriate disinfectant solution before administration.
8) After administration, discard the syringe, needle, and any remaining unused materials.
9) When administering this drug to both knees, use separate needles for each area.
10) If there is no improvement in symptoms, do not re-administer.
10. Precautions for storage and handling
1) Keep out of reach of children.
2) Removing medicines from their original container and storing them in another container may cause accidents due to misuse of medicines or cause a decrease in the quality of medicines, so store them in their original containers.
11. Information for experts
1) Pharmacological action
When administered into the joint space in a surgically induced rabbit osteoarthritis model, this drug has an inhibitory effect on reduction of knee joint thickness and inflammatory edema around the joint, reduction of cartilage damage area, inhibition of increase in knee joint elongation angle, inhibition of increase in Makin score of femoral and tibial joint cartilage, inhibition of increase in joint thickness by inhibiting reduction in articular cartilage thickness and number of chondrocytes, and anti-inflammatory effect through inhibition of inflammatory cytokines IL-1β and TNF-α activity.
2) Pharmacokinetic information
① Absorption: After intra-articular administration of this drug in non-fasting rats, the maximum plasma concentration (Cmax) was reached 1 hour after administration, and the median maximum plasma concentration was reached at 9.88 hours. After subcutaneous administration in non-fasting rats, the maximum plasma concentration (Cmax) was reached 1 hour after administration, and the median maximum plasma concentration was reached at 452 hours.
② Distribution: After 2,400 hours of intra-articular administration, it was confirmed that 73.98% of the administered dose remained in most joint spaces, and it was distributed to all tissues, and over time, the concentration in all tissues except the administration site decreased. Even when administered subcutaneously, it was distributed to all tissues and the concentration decreased in all tissues over time, but it was confirmed that it was eliminated more slowly than when administered intraarticularly.
③ Metabolism: After subcutaneous administration of this drug, it was confirmed that various metabolites with a molecular weight of 21,100 Da or less were present in the plasma, and that metabolites with a molecular weight of 6,100 Da or less were mainly excreted in urine, which is the main excretion route.
④ Excretion: After intraarticular administration, 26.9% and 5.1% of this drug were observed in urine and feces, respectively, and 68.8% of the administered dose was observed at the administration site. After subcutaneous administration, 19.9% and 3.7% were observed in urine and feces, and 74.6% of the administered dose was observed in all tissues.
3) Clinical trial information
① Double-blind, placebo-controlled clinical trial (YY_YYD302_001/2a)
A multicenter, randomized, placebo-controlled, double-blind trial was conducted to compare and evaluate the safety and effectiveness of the three groups when administering this drug and a placebo control once to patients with osteoarthritis of the knee joint. The results of comparing the change in pain score (WBP-100mm VAS: pain evaluation during weight bearing) at 12 weeks after administration of this drug (2mL: 12 people, 3mL: 12 people) and placebo group (3mL: 6 people). There was a statistically significant decrease to -34.20±24.10, -23.10±21.79, and -29.00±33.15 in the this drug (2mL) group, this drug (3mL) group, and placebo (3mL) group, respectively.
② Double-blind, active-controlled clinical trial (YY_YYD302_003)
A multicenter, randomized, active-controlled, double-blind trial was conducted to compare and evaluate the safety and efficacy between the two groups when administering this drug and the active comparator drug (Sinobian) once to patients with osteoarthritis of the knee joint. As a result of comparing the pain scores (WBP-100mm VAS: pain evaluation during weight bearing) at 12 weeks after administration of this drug (95 people) and the active comparator (88 people) (PP group), the WBP-100mm VAS decreased by an average of 31.76 ± 18.93 mm for this drug and 29.74 ± 20.54 mm for the active comparator compared to the baseline, and non-inferiority between the two groups was statistically confirmed. Proven.
③ Re-administration clinical trial (YY_YYD302_003)
To confirm the safety and efficacy of this drug for up to 6 months after a single dose in patients with osteoarthritis of the knee, and to additionally evaluate the safety and efficacy of re-administration, a multicenter, randomized, active-controlled, double-blind study was included in this clinical trial.
After one dose of this drug (80 patients, PP group), WBP-100mm VAS decreased by an average of 39.06 ± 13.15 mm at 12 weeks and 37.72 ± 16.83 mm at 24 weeks compared to baseline. The WBP-100mm VAS at week 36 of patients (47 patients) who were re-administered at week 24 decreased by an average of 5.45±13.14 mm compared to baseline (week 24). The safety and effectiveness of long-term use beyond the period revealed through clinical research have not been confirmed.
4) Toxicity test
① Single-dose toxicity
When a single dose was administered up to the maximum dose (MFD) that can be administered intraperitoneally and intraarticularly to rats and beagle dogs, the lethal dose exceeded the MFD in both sexes, and no dead animals were found.
② Repeated toxicity
This drug was administered intraarticularly to rats at doses of 30, 60, and 120 μL/head/day, repeated eight times at 4-week intervals, and to beagle dogs, this drug was administered intraarticularly at doses of 2, 4, and 6 mL/head/day, repeated eight times at intervals of 16 and 40 weeks. No toxicologically significant changes were observed at any dose.
③ Genotoxicity
The genotoxicity test results of the reverse mutation test using bacteria, the chromosomal abnormality test using CHL cells, and the ICR mouse micronucleus test did not show mutagenicity or cause chromosomal abnormality.
④ Antigenicity
It did not show antigenicity in the anaphylactic shock (ASA) reaction test using Hartley guinea pigs and the allogeneic passive cutaneous anaphylaxis (PCA) reaction test.
5. How to save
Sealed container, stored at room temperature (1~30℃)
6. Packaging unit
2.0mL/prefilled syringe*1
- Active ingredient: 4:1 w/w mixed gel of sodium hyaluronate gel and sodium hyaluronate solution cross-linked with divinyl sulfone (in-house specification) --- 2.04g (40mg as sodium hyaluronate)
- Additives: Sterile needle
2. Effectiveness
osteoarthritis of the knee joint
3. Dosage and dosage
Adults: Administer 1 tube at a time into the knee joint cavity, but administer appropriately considering the interval of administration (6 months or more) depending on symptoms.
4. Precautions for use
1. Do not administer to the following patients:
1) Patients with a history of hypersensitivity to this drug or its components
2) Patients with infection or severe inflammation in the joint space of administration
3) Patients with infection or skin disease on the skin at the injection site
2. Administer with caution to the following patients:
1) Patients with a history of hypersensitivity to other drugs
2) Patients with hepatic impairment or its history
3. Adverse reactions
1) No serious adverse reactions related to this drug occurred.
2) In a clinical trial (YY_YYD302_003) of this drug in patients with knee osteoarthritis using Shinobianju as the control group, the frequency of adverse reactions at the injection site following intra-articular administration was 48.42% (46/95 patients) after the first administration of this drug and 47.27% (26/55 patients) after re-administration. Reported injection site adverse reactions are listed in Table 1 below. Severe adverse reactions were reported in the following order: swelling (9.47% for this drug, 7.27% after re-administration of this drug), erythema (6.32%, 3.64% after re-administration of this drug), and pain (3.16% for this drug, 12.73% after re-administration of this drug). Adverse reactions at the injection site that persisted for more than 7 days after administration of this drug were pain 5.26%, heat 3.16%, and swelling 1.05%, all of which disappeared within 14 days without special treatment. After re-administration, pain 10.91%, swelling 5.45%, heat 3.64%, and erythema 1.82% all disappeared without special treatment.
Table 1. Adverse reactions at the injection site reported in the first administration and re-administration clinical trial of this drug (YY_YYD302_003)
*Table 1. : Refer to manual
3) In a clinical trial of this drug (YY_YYD302_003) using Shinobianju as the control group for patients with knee osteoarthritis, the frequency of adverse reactions excluding injection site reactions was 9.47% (9/95 patients, 19 cases) during the 12 weeks after the first administration of this drug and 29.09% (16/55 patients, 35 cases) during the 36 weeks after the first administration of this drug. The rate was 14.55% (8/55 people, 13 cases) for 12 weeks after re-administration of the drug. Most cases were mild to moderate. Adverse reactions reported with a frequency of more than 1% after administration of this drug are listed in Table 2 below.
Table 2. Adverse reactions reported by more than 1% in the first administration and re-administration clinical trials of this drug (YY_YYD302_003)
*Table 2. : Refer to manual
4. General precautions
1) If there is severe inflammation in the joint due to osteoarthritis of the knee, administration of this drug may cause worsening of local inflammatory symptoms, so it is advisable to administer this drug after eliminating the inflammatory symptoms.
2) Since local pain, erythema, and swelling are very common with the administration of this drug, avoid vigorous exercise or actions that put strain on the joints for 48 hours after administering this drug to the joint space, and take measures such as instructing local rest.
3) This drug may cause pain if it leaks outside the joint space, so be sure to administer it within the joint space.
4) This drug must be administered by an experienced doctor.
5. Interaction
The safety and effectiveness of interactions between this drug and other intra-articular agents have not been proven, so do not administer it together.
6. Administration to pregnant and lactating women
The safety and effectiveness of this drug in pregnant and lactating women have not been established, so administration of this drug is not recommended.
7. Administration to children
Because the safety and effectiveness of this drug in children have not been established, its administration is not recommended.
8. Administration to elderly people
In general, elderly people have reduced physiological function, so caution should be exercised when administering this drug. In two clinical trials, 55.4% (118/213 people) of the total test subjects were elderly people aged 65 years or older who were administered this drug, and there was no difference in response to the drug between elderly and non-elderly people.
9. Application precautions
1) Since this drug is administered into the knee joint space, it must be administered under strict sterile conditions.
2) If there is retention of joint fluid, remove the exudate by paracentesis as necessary and then administer the drug.
3) Do not administer intravascularly, extra-articularly, or into synovial tissue.
4) It is recommended to administer this medicine using the enclosed needle.
5) Be careful because this drug may cause precipitation due to quaternary ammonium salts such as benzalkonium chloride, a disinfectant, and chlorhexidine.
6) This medicine is for one-time use and cannot be re-sterilized or reused. Do not use if package or syringe is open or appears damaged.
7) The injection site must be disinfected with alcohol or other appropriate disinfectant solution before administration.
8) After administration, discard the syringe, needle, and any remaining unused materials.
9) When administering this drug to both knees, use separate needles for each area.
10) If there is no improvement in symptoms, do not re-administer.
10. Precautions for storage and handling
1) Keep out of reach of children.
2) Removing medicines from their original container and storing them in another container may cause accidents due to misuse of medicines or cause a decrease in the quality of medicines, so store them in their original containers.
11. Information for experts
1) Pharmacological action
When administered into the joint space in a surgically induced rabbit osteoarthritis model, this drug has an inhibitory effect on reduction of knee joint thickness and inflammatory edema around the joint, reduction of cartilage damage area, inhibition of increase in knee joint elongation angle, inhibition of increase in Makin score of femoral and tibial joint cartilage, inhibition of increase in joint thickness by inhibiting reduction in articular cartilage thickness and number of chondrocytes, and anti-inflammatory effect through inhibition of inflammatory cytokines IL-1β and TNF-α activity.
2) Pharmacokinetic information
① Absorption: After intra-articular administration of this drug in non-fasting rats, the maximum plasma concentration (Cmax) was reached 1 hour after administration, and the median maximum plasma concentration was reached at 9.88 hours. After subcutaneous administration in non-fasting rats, the maximum plasma concentration (Cmax) was reached 1 hour after administration, and the median maximum plasma concentration was reached at 452 hours.
② Distribution: After 2,400 hours of intra-articular administration, it was confirmed that 73.98% of the administered dose remained in most joint spaces, and it was distributed to all tissues, and over time, the concentration in all tissues except the administration site decreased. Even when administered subcutaneously, it was distributed to all tissues and the concentration decreased in all tissues over time, but it was confirmed that it was eliminated more slowly than when administered intraarticularly.
③ Metabolism: After subcutaneous administration of this drug, it was confirmed that various metabolites with a molecular weight of 21,100 Da or less were present in the plasma, and that metabolites with a molecular weight of 6,100 Da or less were mainly excreted in urine, which is the main excretion route.
④ Excretion: After intraarticular administration, 26.9% and 5.1% of this drug were observed in urine and feces, respectively, and 68.8% of the administered dose was observed at the administration site. After subcutaneous administration, 19.9% and 3.7% were observed in urine and feces, and 74.6% of the administered dose was observed in all tissues.
3) Clinical trial information
① Double-blind, placebo-controlled clinical trial (YY_YYD302_001/2a)
A multicenter, randomized, placebo-controlled, double-blind trial was conducted to compare and evaluate the safety and effectiveness of the three groups when administering this drug and a placebo control once to patients with osteoarthritis of the knee joint. The results of comparing the change in pain score (WBP-100mm VAS: pain evaluation during weight bearing) at 12 weeks after administration of this drug (2mL: 12 people, 3mL: 12 people) and placebo group (3mL: 6 people). There was a statistically significant decrease to -34.20±24.10, -23.10±21.79, and -29.00±33.15 in the this drug (2mL) group, this drug (3mL) group, and placebo (3mL) group, respectively.
② Double-blind, active-controlled clinical trial (YY_YYD302_003)
A multicenter, randomized, active-controlled, double-blind trial was conducted to compare and evaluate the safety and efficacy between the two groups when administering this drug and the active comparator drug (Sinobian) once to patients with osteoarthritis of the knee joint. As a result of comparing the pain scores (WBP-100mm VAS: pain evaluation during weight bearing) at 12 weeks after administration of this drug (95 people) and the active comparator (88 people) (PP group), the WBP-100mm VAS decreased by an average of 31.76 ± 18.93 mm for this drug and 29.74 ± 20.54 mm for the active comparator compared to the baseline, and non-inferiority between the two groups was statistically confirmed. Proven.
③ Re-administration clinical trial (YY_YYD302_003)
To confirm the safety and efficacy of this drug for up to 6 months after a single dose in patients with osteoarthritis of the knee, and to additionally evaluate the safety and efficacy of re-administration, a multicenter, randomized, active-controlled, double-blind study was included in this clinical trial.
After one dose of this drug (80 patients, PP group), WBP-100mm VAS decreased by an average of 39.06 ± 13.15 mm at 12 weeks and 37.72 ± 16.83 mm at 24 weeks compared to baseline. The WBP-100mm VAS at week 36 of patients (47 patients) who were re-administered at week 24 decreased by an average of 5.45±13.14 mm compared to baseline (week 24). The safety and effectiveness of long-term use beyond the period revealed through clinical research have not been confirmed.
4) Toxicity test
① Single-dose toxicity
When a single dose was administered up to the maximum dose (MFD) that can be administered intraperitoneally and intraarticularly to rats and beagle dogs, the lethal dose exceeded the MFD in both sexes, and no dead animals were found.
② Repeated toxicity
This drug was administered intraarticularly to rats at doses of 30, 60, and 120 μL/head/day, repeated eight times at 4-week intervals, and to beagle dogs, this drug was administered intraarticularly at doses of 2, 4, and 6 mL/head/day, repeated eight times at intervals of 16 and 40 weeks. No toxicologically significant changes were observed at any dose.
③ Genotoxicity
The genotoxicity test results of the reverse mutation test using bacteria, the chromosomal abnormality test using CHL cells, and the ICR mouse micronucleus test did not show mutagenicity or cause chromosomal abnormality.
④ Antigenicity
It did not show antigenicity in the anaphylactic shock (ASA) reaction test using Hartley guinea pigs and the allogeneic passive cutaneous anaphylaxis (PCA) reaction test.
5. How to save
Sealed container, stored at room temperature (1~30℃)
6. Packaging unit
2.0mL/prefilled syringe*1